Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer

Saved in:

Bibliographic Details
Main Authors:	Karen A. Autio, Deaglan J. McHugh, Dana E. Rathkopf, Han Xiao, Swathi Merugu, Phillip Wong, Mehrin Jan, Tanya B. Dorff, Elisabeth I. Heath, Howard I. Scher
Format:	Article
Language:	English
Published:	Innovative Healthcare Institute 2025-04-01
Series:	Journal of Immunotherapy and Precision Oncology
Subjects:	adt biochemical recurrence immunotherapy parp inhibitor prostate cancer
Online Access:	https://jipo.org/doi/pdf/10.36401/JIPO-24-36
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
by: Li‐Min Wang, et al.
Published: (2023-01-01)

Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients
by: Maria Delgado-Ortet, et al.
Published: (2025-06-01)

Radical Prostatectomy in Multimodal Setting: Current Role of Neoadjuvant and Adjuvant Hormonal or Chemotherapy-Based Treatments
by: Marco Oderda, et al.
Published: (2025-02-01)

Development and evaluation of a 99mTc-labeled olaparib analog for PARP imaging
by: Wei Xu, et al.
Published: (2025-07-01)

Enhanced tumor suppression in patient-derived temozolomide-resistant glioblastoma cells using a combination treatment of Olaparib and FK866
by: Xiaowei Sha, et al.
Published: (2025-07-01)

The poly (ADP-ribose) polymerase inhibitor olaparib attenuates established pulmonary fibrosis in a large animal model
by: Habtamu B. Derseh, et al.
Published: (2025-08-01)

B7–H3 and c-MET in advanced prostate cancer: exploring possibilities of novel bi-specific drug development
by: Weiying He, et al.
Published: (2025-06-01)

Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
by: Christoph Rogmans, et al.
Published: (2024-11-01)

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging
by: Gianluca Destro, et al.
Published: (2025-07-01)

Comparison Study of the Safety Profile of Olaparib Versus Niraparib: Analysis of Real-World Data from EudraVigilance
by: Desirèe Speranza, et al.
Published: (2025-04-01)

Four-year recurrence-free survival in metastatic uterine adenosarcoma with somatic BRCA2 mutation on olaparib therapy: A case report
by: Katie Foug, et al.
Published: (2025-04-01)

Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer
by: Mengqiu Huang, et al.
Published: (2024-10-01)

Satellite Radar Altimetry Supporting Coastal Hydrology: Case Studies of Guadalquivir River Estuary and Ebro River Delta (Spain)
by: Jesus Gomez-Enri, et al.
Published: (2024-01-01)

PARP9 and PARP14 are involved in microglia-mediated neuroinflammation in Alzheimer′s disease
by: HUANG Lian, WEI Hui
Published: (2025-05-01)

PARP9-PARP13-PARP14 axis tunes colorectal cancer response to radiotherapy
by: Rimvile Prokarenkaite, et al.
Published: (2025-07-01)

Edge protection along haul roads in mines and quarries: A rigorous study based on full-scale testing and numerical modelling
by: Klaus Thoeni, et al.
Published: (2025-07-01)

Proton Exchange Membrane Fuel Cell Stack Durability Prediction Using Arrhenius-Based Accelerated Degradation Model
by: Youngjin Choi, et al.
Published: (2025-01-01)

ATP-Dependent Chromatin Remodeler CSB Couples DNA Repair Pathways to Transcription with Implications for Cockayne Syndrome and Cancer Therapy
by: Rabeya Bilkis, et al.
Published: (2025-02-01)

PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology
by: Barbara Morone, et al.
Published: (2024-01-01)

The role of Poly-ADP ribose polymerase (PARP) enzymes in chemotherapy-induced cognitive impairments – parallels with other neurodegenerative disorders
by: Dahlia A. Ordaz, et al.
Published: (2025-06-01)

Clinical Outcomes of Poly(ADP–Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea
by: Hyeong In Ha, et al.
Published: (2024-10-01)

Excessive exercise elicits poly (ADP-ribose) Polymerase-1 activation and global protein PARylation driving muscle dysfunction and performance impairment
by: Barbara M. Crisol, et al.
Published: (2025-06-01)

DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment
by: Jeong Min Lee, et al.
Published: (2025-01-01)

Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1
by: Ibrahim Morgan, et al.
Published: (2025-06-01)

A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
by: О. N. Churuksaeva, et al.
Published: (2023-09-01)

ADP-ribose hydrolases: biological functions and potential therapeutic targets
by: Jingpeng Wang, et al.
Published: (2024-01-01)

RET Inhibitor SPP86 Is a Potential Candidate for the Clinical Treatment of Cutaneous Melanoma [Letter]
by: Tan Y, et al.
Published: (2025-02-01)

Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors
by: Jiang Yu, et al.
Published: (2022-12-01)

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
by: Álvaro Lahiguera, et al.
Published: (2020-05-01)

Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer Models
by: Yuan Gao, et al.
Published: (2025-08-01)

Development of an Integrated Computational Pipeline for PARP‐1 Inhibitor Screening Using Hybrid Virtual Screening and Molecular Dynamics Simulations
by: Guan Wang, et al.
Published: (2025-08-01)

PARP-1 as a novel target in endocrine-resistant breast cancer
by: Azzurra Zicarelli, et al.
Published: (2025-06-01)

A PARP inhibitors in the treatment of breast cancer - A Review of literature
by: Jagoda Niewiadomska, et al.
Published: (2024-11-01)

The PARPscore system using poly (ADP-ribose) polymerase (PARP) family features and tumor immune microenvironment in glioma
by: Cheng Zhang, et al.
Published: (2024-12-01)

Pyridazine Based Compounds with PARP-1 Inhibitory Activity
by: Norhan A. Abdelrahman, et al.
Published: (2023-12-01)

Phase I Clinical Trial of CVL218, a Novel PARP1/2 Inhibitor, in Patients with Advanced Solid Tumors
by: Zihong Chen, et al.
Published: (2025-07-01)

Parp1 deletion rescues cerebellar hypotrophy in xrcc1 mutant zebrafish
by: Svetlana A. Semenova, et al.
Published: (2025-05-01)

Computer‐aided biochemical programming of synthetic microreactors as diagnostic devices
by: Alexis Courbet, et al.
Published: (2018-04-01)

Biochemical study of some microalgae and using it production of biofuel
by: Muhanad H. S. Al-Jubori, et al.
Published: (2023-01-01)

PARP Inhibition in Colorectal Cancer—A Comparison of Potential Predictive Biomarkers for Therapy
by: Abdulaziz Alfahed
Published: (2025-06-01)